+

WO2001068698A3 - Nouveau canal cationique non selectif - Google Patents

Nouveau canal cationique non selectif Download PDF

Info

Publication number
WO2001068698A3
WO2001068698A3 PCT/EP2001/002837 EP0102837W WO0168698A3 WO 2001068698 A3 WO2001068698 A3 WO 2001068698A3 EP 0102837 W EP0102837 W EP 0102837W WO 0168698 A3 WO0168698 A3 WO 0168698A3
Authority
WO
WIPO (PCT)
Prior art keywords
otrpc4
activators
modulators
blocking agents
relates
Prior art date
Application number
PCT/EP2001/002837
Other languages
German (de)
English (en)
Other versions
WO2001068698A2 (fr
Inventor
Guenter Schultz
Timothy Plant
Rainer Strotmann
Christian Harteneck
Karin Nunnenmacher
Original Assignee
Boehringer Ingelheim Pharma
Guenter Schultz
Timothy Plant
Rainer Strotmann
Christian Harteneck
Karin Nunnenmacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Guenter Schultz, Timothy Plant, Rainer Strotmann, Christian Harteneck, Karin Nunnenmacher filed Critical Boehringer Ingelheim Pharma
Publication of WO2001068698A2 publication Critical patent/WO2001068698A2/fr
Publication of WO2001068698A3 publication Critical patent/WO2001068698A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des acides nucléiques qui codent les canaux cationiques non sélectifs OTRPC4, ainsi que des polypeptides qui sont codés par lesdits acides nucléiques. La présente invention concerne également des hôtes ou des cellules hôtes qui expriment ledit polypeptide, ainsi qu'un procédé de détection d'inhibiteurs, d'activateurs et de modulateurs desdits canaux cationiques OTRPC4. Cette invention concerne également des inhibiteurs, des activateurs et des modulateurs desdits canaux cationiques OTRPC4, ainsi que des compositions pharmaceutiques contenant lesdits inhibiteurs, activateurs et modulateurs. En outre, cette invention concerne des mammifères non humains, qui contiennent OTRPC4 en tant que transgène, que gène inactivé (knock-out) ou que gène modifié (knock-in).
PCT/EP2001/002837 2000-03-17 2001-03-14 Nouveau canal cationique non selectif WO2001068698A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10013296A DE10013296A1 (de) 2000-03-17 2000-03-17 Neuer nichtselektiver Kationenkanal
DE10013296.0 2000-03-17

Publications (2)

Publication Number Publication Date
WO2001068698A2 WO2001068698A2 (fr) 2001-09-20
WO2001068698A3 true WO2001068698A3 (fr) 2002-06-20

Family

ID=7635294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002837 WO2001068698A2 (fr) 2000-03-17 2001-03-14 Nouveau canal cationique non selectif

Country Status (2)

Country Link
DE (1) DE10013296A1 (fr)
WO (1) WO2001068698A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1497328A2 (fr) * 2002-04-16 2005-01-19 Bayer HealthCare AG Regulation de canal potentiel recepteur transitoire humain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032766A1 (fr) * 1998-12-01 2000-06-08 Glaxo Group Limited Proteines humaines receptrices de vanilloide et leurs utilisations
WO2001034805A2 (fr) * 1999-11-12 2001-05-17 Abbott Laboratories Gene de recepteur de vanilloide humain
WO2001046258A2 (fr) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporteurs et canaux ioniques
WO2001053348A2 (fr) * 2000-01-21 2001-07-26 Bristol-Myers Squibb Company Nouvelles molecules d'acide nucleique humain et polypeptides codant pour des canaux cationiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032766A1 (fr) * 1998-12-01 2000-06-08 Glaxo Group Limited Proteines humaines receptrices de vanilloide et leurs utilisations
WO2001034805A2 (fr) * 1999-11-12 2001-05-17 Abbott Laboratories Gene de recepteur de vanilloide humain
WO2001046258A2 (fr) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporteurs et canaux ioniques
WO2001053348A2 (fr) * 2000-01-21 2001-07-26 Bristol-Myers Squibb Company Nouvelles molecules d'acide nucleique humain et polypeptides codant pour des canaux cationiques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CATERINA ET AL: "A capsaicin-receptor homologue with a high threshold for noxious heat", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 398, 1 April 1999 (1999-04-01), pages 436 - 441, XP002105951, ISSN: 0028-0836 *
CATERINA M J ET AL: "THE CAPSAICIN RECEPTOR: A HEAT-ACTIVATED ION CHANNEL IN THE PAIN PATHWAY", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 389, 23 October 1997 (1997-10-23), pages 816 - 824, XP002075020, ISSN: 0028-0836 *
DATABASE EBI 1 November 2000 (2000-11-01), LIEDTKE, W. B. ET AL.: "Homo sapiens vanilloid receptor-related osmotically activated channel (VROAC) mRNA, complete cds", XP002182929 *
DATABASE EBI 12 September 2000 (2000-09-12), DELANY, N. S. ET AL.: "Human vanilloid receptor 3 coding sequence", XP002182928 *
DATABASE EBI 3 September 1999 (1999-09-03), SUZUKI, M.: "Mus musculus mRNA for ion channel, complete cds", XP002182927 *
LIEDTKE, W. ET AL.: "Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor", CELL, vol. 103, October 2000 (2000-10-01), pages 525 - 535, XP002182926 *

Also Published As

Publication number Publication date
DE10013296A1 (de) 2001-09-20
WO2001068698A2 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
ATE370232T1 (de) Anti-apo-2 antikörper
DK1448595T3 (da) Antimikrobielle polypeptider
WO1999054459A8 (fr) Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
WO2002012525A3 (fr) Nouvelles fonctions auxiliaires destinees a la production de vecteurs recombinants
HK1038929A1 (en) Cancer antigens based on tumor suppressor gene wt1product.
EP2295555A3 (fr) Polypeptides dotés d'activité lipase et polynucléotides les codant
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
EP0832975A3 (fr) Histidinol déshydrogénase de Staphylococcus aureus
AU2003291962A1 (en) Polypeptides having cellobiohydrolase ii activity and polynucleotides encoding same
CA2315274A1 (fr) Polypeptides a activite aminopeptidase, et acides nucleiques codant ces polypeptides
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
EP1383903A4 (fr) Production de substances dans des cellules hotes
DE69534776D1 (de) Klonierung und expression von einer acetylcholin-durchlässigen ionenkanälen rezeptor-untereinheit
WO2002074807A3 (fr) Immunoadhesines d'erythropoietine de chimpanze (chepo)
WO2002041911A3 (fr) Methodes de modulation de l'angiogenese
DK1157100T3 (da) Oxaloacetathydrolase-defekte svampeværtsceller
AU1691588A (en) A fibronectin binding protein as well as its preparation
WO2001019861A3 (fr) Anticorps du recepteur d'apo-2
EP0962530A3 (fr) Séquence du gène codant pour la protéine scarface 1 apparentée a l'angiopoiétine
WO2001068698A3 (fr) Nouveau canal cationique non selectif
AU2002350545A1 (en) Use of the adenoviral e2 late promoter
WO2000052179A3 (fr) Syteme de sequence activatrice a mediation assuree par compose de liaison a l'adn
WO2001096535A3 (fr) Acide nucleique codant pour un site de liaison d'une proteine kinase de la cascade de signalisation mitogene de l'enzyme catalysant la glycolyse
AU7645400A (en) Polypeptides having glucanotransferase activity and nucleic acids encoding same
NZ501772A (en) Gene encoding protein having aurone synthesizing activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载